JP2010522772A - 腫瘍微小環境の調整 - Google Patents

腫瘍微小環境の調整 Download PDF

Info

Publication number
JP2010522772A
JP2010522772A JP2010501268A JP2010501268A JP2010522772A JP 2010522772 A JP2010522772 A JP 2010522772A JP 2010501268 A JP2010501268 A JP 2010501268A JP 2010501268 A JP2010501268 A JP 2010501268A JP 2010522772 A JP2010522772 A JP 2010522772A
Authority
JP
Japan
Prior art keywords
antibody
cells
malignant
cell
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010501268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522772A5 (enExample
Inventor
カンダサミー ハリハラン，
ステファン ホー，
シャブナム タングリ，
テッド ユン，
アルトゥーロ モリナ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of JP2010522772A publication Critical patent/JP2010522772A/ja
Publication of JP2010522772A5 publication Critical patent/JP2010522772A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010501268A 2007-03-28 2008-03-28 腫瘍微小環境の調整 Pending JP2010522772A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90864507P 2007-03-28 2007-03-28
PCT/US2008/058744 WO2008119071A1 (en) 2007-03-28 2008-03-28 Modulation of tumor microenvironment

Publications (2)

Publication Number Publication Date
JP2010522772A true JP2010522772A (ja) 2010-07-08
JP2010522772A5 JP2010522772A5 (enExample) 2011-05-06

Family

ID=39485176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010501268A Pending JP2010522772A (ja) 2007-03-28 2008-03-28 腫瘍微小環境の調整

Country Status (8)

Country Link
US (1) US20100203010A1 (enExample)
EP (1) EP2139923A1 (enExample)
JP (1) JP2010522772A (enExample)
CN (1) CN101679522A (enExample)
AU (1) AU2008230724A1 (enExample)
BR (1) BRPI0809386A2 (enExample)
CA (1) CA2682027A1 (enExample)
WO (1) WO2008119071A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012026763A (ja) * 2010-07-20 2012-02-09 Mitsuo Takase 解析によるミクロな腫瘍免疫挙動の顕微鏡的把握方法
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
JP2017535543A (ja) * 2014-11-06 2017-11-30 バイオセラ，インク． 腫瘍内微小環境に影響を与えるベータ−グルカン方法と組成物
JP2018524362A (ja) * 2014-03-12 2018-08-30 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． Ｃｎｓの疾患および損傷を処置するための全身における制御性ｔ細胞のレベルまたは活性の低下

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3147297B1 (en) * 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
US9567642B2 (en) 2012-02-02 2017-02-14 Massachusetts Institute Of Technology Methods and products related to targeted cancer therapy
US8961957B2 (en) 2012-06-27 2015-02-24 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
US9907819B2 (en) 2012-06-27 2018-03-06 Kenichiro Hasumi Therapy and methods of introducing immature dendritic cells and/or cytotoxic T lymphocyte and anti-TNF antibody for treatment of tumors
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
WO2015077532A1 (en) * 2013-11-21 2015-05-28 Hasumi International Research Foundation Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti-tnf antibody for treatment of tumors
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US20160206717A1 (en) * 2015-01-16 2016-07-21 Batu Biologics, Inc. Stimulation of immunity to endothelial cells, endothelial-like cells, and intratumor vascular channels derived from tumor tissue
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089567A1 (en) * 2000-05-22 2001-11-29 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
US20050260205A1 (en) * 1995-06-07 2005-11-24 Biogen Idec, Inc. Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens and therapy thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506915A (ja) * 1995-06-07 1999-06-22 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃｄ８０およびｃｄ８６発現細胞に対して特異的なイムノトキシン

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260205A1 (en) * 1995-06-07 2005-11-24 Biogen Idec, Inc. Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens and therapy thereof
WO2001089567A1 (en) * 2000-05-22 2001-11-29 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5010006643; ＹＥＥ　ＫＡＲＥＮ，Ｗ．Ｌ．: Ｅｘｐｅｒｔ　Ｏｐｉｎｉｏｎ　ｏｎ　Ｅｍｅｒｇｉｎｇ　Ｄｒｕｇｓ Ｖｏｌ．１１，　Ｎｏ．１, 2006, ｐ．１６７-１８９ *
JPN5010006645; ＨＡＲＩＨＡＲＡＮ，Ｋ．　ｅｔ　ａｌ: 'Ｔｈｅｒａｐｅｕｔｉｃ　ａｃｔｉｖｉｔｙ　ｏｆ　ＩＤＥＣ-１１４　（ａｎｔｉ-ＣＤ８０）　ａｎｄ　ｒｉｔｕｘｉｍａｂ　（Ｒｉｔｕｘａｎ（Ｒ））　ｉｎ　Ｂ-ｃｅｌｌ　ｌｙｍｐｈｏｍａ' Ｂｌｏｏｄ Ｖｏｌ．９８，　Ｎｏ．１１, 2001, ｐ．６０８ａ *
JPN6012057621; ＣＺＵＣＺＭＡＮ，Ｍ．Ｓ．　ｅｔ　ａｌ: Ｊｏｕｒｎａｌ　ｏｆ　ｃｌｉｎｉｃａｌ　ｏｎｃｏｌｏｇｙ Ｖｏｌ．２３，　Ｎｏ．１９, 2005, ｐ．４３９０-８ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012026763A (ja) * 2010-07-20 2012-02-09 Mitsuo Takase 解析によるミクロな腫瘍免疫挙動の顕微鏡的把握方法
JP2018524362A (ja) * 2014-03-12 2018-08-30 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． Ｃｎｓの疾患および損傷を処置するための全身における制御性ｔ細胞のレベルまたは活性の低下
JP2017535543A (ja) * 2014-11-06 2017-11-30 バイオセラ，インク． 腫瘍内微小環境に影響を与えるベータ−グルカン方法と組成物
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤

Also Published As

Publication number Publication date
CA2682027A1 (en) 2008-10-02
WO2008119071A1 (en) 2008-10-02
CN101679522A (zh) 2010-03-24
US20100203010A1 (en) 2010-08-12
AU2008230724A1 (en) 2008-10-02
AU2008230724A8 (en) 2009-11-26
BRPI0809386A2 (pt) 2014-09-09
EP2139923A1 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
JP2010522772A (ja) 腫瘍微小環境の調整
JP7356531B2 (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用
US8142778B2 (en) Methods of treatment using CTLA-4 antibodies
ES2381557T3 (es) Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
JP2011503098A5 (enExample)
JP2020510435A (ja) 抗ｇｉｔｒ抗体およびその使用方法
JP2022511337A (ja) 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
JP2021501801A (ja) 癌の処置に用いるための免疫刺激アゴニスト抗体
CN102803961A (zh) 新的医学方法以及用于医学方法的药剂
US20100189716A1 (en) Treatment of hodgkins lymphoma
US20210032322A1 (en) Combined inhibition of semaphorin-4d and tgf-beta and compositions therefor
US20230181753A1 (en) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
KR20190034238A (ko) 종양 관련 대식세포를 표적화하는 항체 및 이의 용도
US20250171533A1 (en) Kir3dl3 inhibitors and immune cell activating agents
KR20260026100A (ko) 항-카텝신-d 항체
EP4320153A1 (en) Methods for the treatment of anaplastic large cell lymphoma
WO2022255248A1 (ja) 抗ｃｄ２６抗体と免疫チェックポイント阻害剤との併用療法
HK40118068A (zh) Kir3dl3抑制剂和免疫细胞激活剂
WO2019221574A1 (ko) 골수유래억제세포 관련 질환의 예방 및 치료 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130430